BillionToOne's Nasdaq Debut: A $4.4B Valuation
Update: 2025-11-06
Description
BillionToOne, a molecular diagnostics company, made a strong debut on Nasdaq, with shares surging by 66.67% and a market valuation of $4.4 billion. The company, known for non-invasive blood tests for prenatal care and oncology, reported improved financials, with a net loss of $4.2 million on revenues of $125.5 million for the first half of 2021. Co-founders Oguzhan Atay and David Tsao retain a 64% voting power, while J.P. Morgan, Piper Sandler, Jefferies, and William Blair served as underwriters for the offering.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
